AOD-9604 Research Standard
AOD-9604 (CAS 221231-10-3) is a peptide consisting of the C-terminal fragment of human growth hormone, residues 177–191, with an additional tyrosine residue at the N-terminus. It is also circulated under the name Tyr-hGH fragment 176-191, and both stylings appear in supplier listings — the numbering used here follows the primary analytical characterisation of the molecule.[1]
Mechanism of Action & Research Context
AOD-9604 has no identified receptor. Its documented literature is analytical rather than pharmacological, and the honest framing is that its functional claims are reported rather than established.
What is claimed, and by whom. The peptide is reported to mimic the lipolytic properties of growth hormone without the diabetogenic effects. That is the stated rationale for the molecule, and it is worth reading as a design intent rather than a demonstrated result — the source characterising the compound analytically describes it in exactly those reported terms.[1]
Six metabolites, one that outlasts the parent. Incubation in serum and urine identified six potential metabolites. Quantification in serum found a single metabolite, the sequence CRSVEGSCG, that is significantly more stable than the other metabolites or the parent compound itself. For method development that inverts the usual assumption: the parent is not necessarily the best analyte.[1]
Validated trace detection. A solid-phase extraction method in urine reached a limit of detection of 50 pg/mL with good linearity, precision under 20%, specificity and 62% recovery. Screening for parent and stable metabolite together widens the detection window.[1]
Distinct from Fragment 176-191. The unmodified hGH 176-191 fragment is a different peptide with its own CAS number, lacking the N-terminal tyrosine. They are not interchangeable and should not be treated as the same material.
Research Applications
Primary fields of laboratory investigation include:
Metabolite identification in serum and urine incubations.[1]
Trace-level analytical method development, targeting parent and the stable CRSVEGSCG metabolite together.[1]
Solid-phase extraction and LC-MS/MS validation.[1]
Comparative work against the unmodified 176-191 fragment to isolate what the N-terminal tyrosine contributes.
Analytical Documentation
Purity and identity vary by manufacturing lot. Kimera Chems does not publish a single fixed purity figure for this item; refer to the batch-specific Certificate of Analysis (COA) issued for the lot received, which reflects third-party analytical testing for that lot.
References
- Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31–38. doi:10.1002/dta.1715
Storage & Handling
Store at controlled room temperature. Keep tightly closed.
Storage guidance is a house recommendation. Analytical documentation is per-lot release testing.
